Canada
· Delayed Price · Currency is CAD Cytophage Technologies Statistics
Total Valuation
TSXV:CYTO has a market cap or net worth of CAD 9.71 million. The enterprise value is 9.73 million.
| Market Cap | 9.71M |
| Enterprise Value | 9.73M |
Important Dates
The last earnings date was Thursday, May 1, 2025.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TSXV:CYTO has 53.94 million shares outstanding. The number of shares has increased by 24.44% in one year.
| Current Share Class | 53.94M |
| Shares Outstanding | 53.94M |
| Shares Change (YoY) | +24.44% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 12.53% |
| Owned by Institutions (%) | 2.08% |
| Float | 47.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.31 |
| P/TBV Ratio | 3.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.24 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.60 |
Financial Position
The company has a current ratio of 2.67, with a Debt / Equity ratio of 0.52.
| Current Ratio | 2.67 |
| Quick Ratio | 2.52 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.25 |
| Interest Coverage | -50.63 |
Financial Efficiency
Return on equity (ROE) is -475.94% and return on invested capital (ROIC) is -97.39%.
| Return on Equity (ROE) | -475.94% |
| Return on Assets (ROA) | -62.30% |
| Return on Invested Capital (ROIC) | -97.39% |
| Return on Capital Employed (ROCE) | -121.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.73% in the last 52 weeks. The beta is 0.22, so TSXV:CYTO's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -63.73% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.26 |
| Relative Strength Index (RSI) | 42.23 |
| Average Volume (20 Days) | 46,274 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -5.17M |
| Pretax Income | -7.86M |
| Net Income | -7.86M |
| EBITDA | -4.47M |
| EBIT | -5.17M |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
The company has 1.52 million in cash and 1.54 million in debt, giving a net cash position of -17,394 or -0.00 per share.
| Cash & Cash Equivalents | 1.52M |
| Total Debt | 1.54M |
| Net Cash | -17,394 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 2.93M |
| Book Value Per Share | 0.05 |
| Working Capital | 1.14M |
Cash Flow
In the last 12 months, operating cash flow was -4.77 million and capital expenditures -1.30 million, giving a free cash flow of -6.07 million.
| Operating Cash Flow | -4.77M |
| Capital Expenditures | -1.30M |
| Free Cash Flow | -6.07M |
| FCF Per Share | -0.11 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSXV:CYTO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.44% |
| Shareholder Yield | n/a |
| Earnings Yield | -80.99% |
| FCF Yield | -62.57% |
Stock Splits
The last stock split was on February 9, 2024. It was a reverse split with a ratio of 0.2412662.
| Last Split Date | Feb 9, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.2412662 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |